15 citations
,
March 2007 in “Hormones and Behavior” Finasteride boosts morphine's pain relief, stops tolerance, and reduces withdrawal in rats.
January 2010 in “Chinese Medical Journal of Metallurgical Industry” Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.
24 citations
,
January 2003 in “Journal of Investigative Dermatology” Blocking a specific receptor slows down hair loss in mice.
October 2016 in “Letters in Drug Design & Discovery”
Solanum nigrum may help treat hair loss.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
26 citations
,
February 2020 in “International Journal of Biological Macromolecules” Chitosan-coated dutasteride nanocapsules improve hair treatment, and physical stimulation boosts effectiveness.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” DNCB is more effective than betamethasone for hair regrowth but has more side effects.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
4 citations
,
May 2011 in “Current Drug Discovery Technologies” A new liposomal system for applying dutasteride to the skin was developed, showing better skin absorption and stability, potentially improving treatment for hair loss.
16 citations
,
June 2017 in “JAMA Dermatology” Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
Dutasteride may become the top choice for treating hair loss.
78 citations
,
January 2000 in “Gynecological Endocrinology” Norgestimate is the most effective birth control progestin for reducing an enzyme linked to acne and excessive hair growth in women.
February 2026 in “NeuroSci” Finasteride and dutasteride may cause depression and anxiety, especially in younger men.
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
11 citations
,
December 2010 in “The Journal of Urology” Taking oral testosterone with or without dutasteride increases testosterone levels and could be an effective treatment for low testosterone.
May 2018 in “Dermatologic Surgery” 186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
5 citations
,
September 2012 in “BMJ case reports” Ashwagandha may improve hormone levels and reduce hair loss in non-classical adrenal hyperplasia.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
January 2025 in “Current Trends in Pharmacy and Pharmaceutical Chemistry” New methods for measuring dutasteride are effective and reliable.
4 citations
,
December 2022 in “Frontiers in Endocrinology” Treating non-classic congenital adrenal hyperplasia is complex because the benefits of hormone treatment must be weighed against potential health risks.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
February 2023 in “Reactions Weekly” October 2025 in “Reactions Weekly”